CHICAGO, IL—Patients with stable CAD who respond well to the PCSK9 inhibitor evolocumab (Repatha; Amgen) have differences in gene expression compared with nonresponders, according to new data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback